1787-23-1

Basic information

• Product Name: 4-[4-(Dimethylamino)benzylidene]-2-methyl-1,3-oxazol-5(4H)-one
• Synonyms: 4-[4-(Dimethylamino)benzylidene]-2-methyl-1,3-oxazol-5(4H)-one
• CAS NO: 1787-23-1
• Molecular Formula: C₁₃H₁₄N₂O₂
• Molecular Weight: 230
• Mol File: 1787-23-1.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-[4-(Dimethylamino)benzylidene]-2-methyl-1,3-oxazol-5(4H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[4-(Dimethylamino)benzylidene]-2-methyl-1,3-oxazol-5(4H)-one(1787-23-1)
• EPA Substance Registry System: 4-[4-(Dimethylamino)benzylidene]-2-methyl-1,3-oxazol-5(4H)-one(1787-23-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 1787-23-1(Hazardous Substances Data)

Usage

General Description

The chemical "4-[4-(Dimethylamino)benzylidene]-2-methyl-1,3-oxazol-5(4H)-one" is a synthetic compound with a complex molecular structure. It contains a benzylidene group, a dimethylamino group, and an oxazolone ring. This chemical is commonly used in pharmaceutical research as a building block for the synthesis of potential drug compounds. It has potential applications in the development of pharmaceuticals for various medical conditions, such as cancer, infectious diseases, and neurological disorders. Its unique structure and reactivity make it a valuable tool in drug discovery and development. Further research and exploration of its properties may lead to the discovery of new therapeutic agents with improved efficacy and safety profiles.

Upstream product

• 100-10-7 4-dimethylamino-benzaldehyde 
• 543-24-8 N-acetylglycine 

Downstream Products

• 1384247-31-7 4-(4-dimethylaminobenzylidene)-1-benzyl-2-methylimidazol-5-one 
• 1384247-69-1 N-methyl-2-(acetamido)-3-(4-dimethylaminophenyl)acrylamide 
• 1384247-61-3 N-benzyl-2-(acetamido)-3-(4-dimethylaminophenyl)acrylamide 
• 1575728-56-1 1-(4-chloro-6-methylpyrimidin-2-yl)-4-(4-(dimethylamino)benzylidene)-2-phenyl-1H-imidazol-5(4H)-one 
• 1575728-38-9 1-(4-chloro-6-methylpyrimidin-2-yl)-4-(4-(dimethylamino)benzylidene)-2-methyl-1H-imidazol-5(4H)-one 
• 1575727-93-3 4-(4-(dimethyl amino) benzylidene)-1-(4-hydroxy-6-methylpyrimidin-2-yl)-2-phenyl-1H-imidazol-5(4H)-one 
• 1575727-70-6 4-(4-(dimethylamino)benzylidene)-1-(4-hydroxy-6-methylpyrimidin-2-yl)-2-methyl-1H-imidazol-5(4H)-one 
• 1373956-82-1 4-(4-(dimethylamino)benzylidene)-2-methyl-1-(pyridin-4-ylmethyl)-1H-imidazol-5(4H)-one 
• 148874-99-1 N-[(2-{4-[1-(4-Dimethylamino-phenyl)-meth-(Z)-ylidene]-2-methyl-5-oxo-4,5-dihydro-imidazol-1-yl}-phenylcarbamoyl)-methyl]-benzamide 
• 140935-45-1 2-(Benzothiazol-2-ylsulfanyl)-N-{4-[1-(4-dimethylamino-phenyl)-meth-(Z)-ylidene]-2-methyl-5-oxo-4,5-dihydro-imidazol-1-yl}-acetamide 
• 140935-55-3 2-(Benzooxazol-2-ylsulfanyl)-N-{4-[1-(4-dimethylamino-phenyl)-meth-(Z)-ylidene]-2-methyl-5-oxo-4,5-dihydro-imidazol-1-yl}-acetamide 

Relevant articles and documents

Fluorescent dye probe for latent fingerprint detection and preparation method and application thereof

The invention relates to a fluorescent dye probe for latent fingerprint detection and a preparation method and application thereof, wherein the core chemical structural formula of the probe is shown I. In-flight R1 The aromatic ring (comprising

Dual-Emission GFP Chromophore-Based Derivative for Imaging and Discriminating Aβ Oligomers and Aggregates

β-Amyloid deposition is one of the main pathological features of Alzheimer’s disease (AD). The development of fluorescent probes targeting specific β-amyloid species has recently become an attractive strategy to achieve the early diagnosis of AD. In this

Synthesis, in-vitroreverse transcriptase inhibitory activity and docking study of some new imidazol-5-one analogs

Non-nucleoside reverse transcriptase inhibitors have a definitive role and most commonly used in treatment of HIV-1 infection. A new series of 4-ethylidene/substituted-benzylidene-1-(4-hydroxy/chloro-6-methylpyrimidin-2-yl) -2-ethyl/phenyl-1H-imidazol-5(4H)-one were designed, synthesized, and evaluated for HIV-1 reverse transcriptase (RT) inhibitory activity. The results of in-vitro HIV-1 RT assay showed that some of the new compounds, such as 4c, 4d, 4e, 5a, and 5e effectively inhibit HIV-1 RT activity. 1-(4-Chloro-6- methylpyrimidin-2-yl)-4-(furan-2-ylmethylene)-2-methyl-1H-imidazol-5(4H)-one (5e) exerted most potent in-vitro HIV-1 RT inhibitory activity, among the group of compounds. Molecular docking studies were carried out to explore the binding affinity of imidazole-5-one analogs in active site of HIV-1 RT enzyme. Springer Science+Business Media 2014.